Atricure provides atrial fibrillation solutions worldwide. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The company was founded in 2000 and is based in West Chester, Ohio.
Thinly traded AtriCure ([[ATRC]] -9.4%) is under modest pressure out of the gate this morning on the heels of a bearish report from Kerrisdale Capital Management who believes its growth drivers face headwinds. Key points:The company's Convergent procedure is unlikely to gain traction considering its poor safety profile and lack...
Kerrisdale Capital is short shares of AtriCure, Inc. Q2 2020 hedge fund letters, conferences and more We are short shares of AtriCure, a $1.9bn medical device company that manufactures and sells ablation equipment used in the surgical treatment of atrial fibrillation (AF). At about 7x forward revenues, AtriCure’s valuation implies that the company’s outlook is […] The post Kerrisdale: AtriCure Inc. (ATRC) Revenue Growth is Set to Short-Circuit appeared first on ValueWalk .
AtriCure (ATRC) is a company not well-covered on this platform. Early 2017, I last reviewed the investment outlook for the shares as I concluded that management would need to find a cure for continued losses. Steady revenue growth and expectations of investors that the business would become profitable have been...
The Value Investor on Seeking Alpha | September 18, 2020
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 18th Annual Global Healthcare Conference being held virtually. AtriCure’s management is scheduled to present on Monday, September 14, 2020, at 2:15 p.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by vi
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal reasons and moving into an advisory role through March 5, 2021. Angie Wirick, current Vice President of Finance, has been promoted to CFO effective immediately. “On behalf of our team at AtriCure and our Board of Dire